Key result
Sunitinib and sorafenib caused distinct myocardial and mitochondrial toxicities in rat models, whereas pazopanib did not, suggesting cardiotoxicity is not a classwide effect of VEGFR inhibition.
Why the study?
Do sunitinib, sorafenib, and pazopanib have different cardiotoxic effects on myocardial function and structure in rat models?
Do sunitinib, sorafenib, and pazopanib have different cardiotoxic effects on myocardial function and structure in rat models?
Cardiotoxicity of multikinase angiogenesis inhibitors is not a class-wide effect of VEGFR inhibition and may instead be driven by off-target kinase inhibition leading to mitochondrial toxicity.
No takes yet. Share an insight, caveat, or question.
Supports differential VEGFR TKI cardiotoxicity in rats; leaves open human translation and off-target mechanisms.
French et al. (2010) studied Cardiotoxicity. Sunitinib, sorafenib, and pazopanib was evaluated on Myocardial function and structure. Sunitinib and sorafenib caused distinct myocardial and mitochondrial toxicities in rat models, whereas pazopanib did not, suggesting cardiotoxicity is not a classwide effect of VEGFR inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: